Qiagen

Boundless Bio Appoints Peter Krein, Ph.D., as Vice President, Precision Medicine

Retrieved on: 
Monday, January 17, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Doctor of Philosophy, Peter, Patient, Boundless, Precision medicine, Lilly, Genomics, Luminex Corporation, Medical Affairs Bureau, Bio, DNA, Cancer, University, Drug development, Therapy, Qiagen, Rolling circle replication, Neoplasm, Medical imaging

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that Peter Krein has been appointed as Vice President of Precision Medicine.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that Peter Krein has been appointed as Vice President of Precision Medicine.
  • We are thrilled to welcome Peter to our growing team, said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
  • Previously, Peter served as Executive Director, Diagnostic Development and Medical Affairs at Loxo Oncology at Lilly, where he led global diagnostic strategies for precision oncology therapeutics.
  • I look forward to contributing to Boundless Bios precision oncology strategy and capabilities to treat patients with ecDNA driven gene amplification.

Global Chemiluminescence Immunoassay Market Report 2021-2028 - Focus on Consumables, Instruments, Software & Services - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022
Biotechnology, Health, Oncology, CAGR, Application, DiaSorin, American Cancer Society, Severe acute respiratory syndrome coronavirus 2, Adoption, CLIA, Disease, Solution, Software, HIV, Consumables, WHO, Qiagen, Cancer, Prevalence, Hospital, Conditional sentence, Endocrinology, Awareness, Medical device, Vaccine, Video game

The "Global Chemiluminescence Immunoassay Market Size, Share & Trends Analysis Report by Product (Consumables, Instruments, Software & Services), by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chemiluminescence Immunoassay Market Size, Share & Trends Analysis Report by Product (Consumables, Instruments, Software & Services), by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • Key players in the market are implementing organic and inorganic growth strategies for the development, launch, and distribution of novel CLIA solutions.
  • However, the high setup cost of automated chemiluminescence immunoassay systems is expected to be a major factor hindering the market growth.
  • The emergence of local players in developing markets, such as India and China, is primarily driving the regional market

Global Circulating Tumor Cells (CTC) Markets, 2021-2026: Emergence of New Single-Cell Technologies & Increasing R&D Activities in CTC Analysis and Detection Practices - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 13, 2022
Biotechnology, Health, Oncology, CAGR, Research, Mobile, CTC, Blood, Incidence, Competitive analysis, RNA, Miltenyi Biotec, Bone marrow, Midsayap Diagnostic Center and Hospital, System, International Roadmap for Devices and Systems, Academic institution, Global, Geography, Clifton Springs Hospital & Clinic, Diagnosis, COVID-19, Hospital, Device, Qiagen, Technology, USD, Cancer, Fluid mechanics, Chinese, Medicine, Impact, Awareness, Medical imaging, Medical device, Application

The Global Circulating Tumor Cells (CTC) Market is estimated to be USD 9.52 Bn in 2021 and is expected to reach USD 18.41 Bn by 2026, growing at a CAGR of 14.1%.

Key Points: 
  • The Global Circulating Tumor Cells (CTC) Market is estimated to be USD 9.52 Bn in 2021 and is expected to reach USD 18.41 Bn by 2026, growing at a CAGR of 14.1%.
  • Key factors such as the growing incidence of cancer followed by the increasing potential of CTCs in diagnosis and treatment have been a prominent driver for the Global Circulating Tumor Cells (CTC) Market.
  • Moreover, stringent government regulations and reluctance to adopt novel CTC technologies are posing to cause significant challenges for the market growth.
  • By Technology, the market is classified as CTC Enrichment, CTC Detection, and CTC Analysis.

Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

Retrieved on: 
Thursday, January 6, 2022
Singular, Disease, George Washington University School of Engineering and Applied Science, Supervisory board, Parliamentary Information Technology Committee, University, Pediatrics, Genetic distance, Doctor of Philosophy, Compensation, Director, Chemistry, Science and Technology Select Committee, Hospital, Proteomics, DNA, G4, Cancer, Ohio State University College of Medicine, Federal, Spatial analysis, Risk, Zoology, Institute, NGS, OMIC, Prognosis, Nationwide, PX, Faculty, Health, SEC, Biochemistry, Precision medicine, Medicine, Qiagen, Board, Genomics, GLOBE, Washington University School of Medicine, Technology, Board of directors, Nasdaq, Solution, Industry, Antibiotics, Management, Science

We are thrilled to have Elaine join the Board of Directors.

Key Points: 
  • We are thrilled to have Elaine join the Board of Directors.
  • She brings the rare combination of world-class scientific, industry and governance talents to the role.
  • Singular Genomics is a science and technology company first.
  • Additionally, Dr. Mardis serves on the Supervisory Board, Science and Technology Committee, and the Compensation and Human Resources Committee at Qiagen.

New Study from StrategyR Highlights a $1.2 Billion Global Market for Next Generation Sequencing (NGS) Data Analysis by 2026

Retrieved on: 
Tuesday, January 4, 2022
Cloud, COVID-19, CAGR, Eurofins Scientific, Growth, Forecasting, Sophia Genetics, Algorithm, Awareness, GIA, Diagnosis, Technology, DNA sequencing, Clinical research, Clifton Springs Hospital & Clinic, Intelligence, Research, Software, Pacific Biosciences, Wellcome Sanger Institute, Breast, NGS, Data lake, Service, Agilent Technologies, Method, Thermo Fisher Scientific, Marketing, Automation, RNA, Hospital, SAN, Globe, Cloud computing, Data analysis, Internet, Players, Geography, DNA, Prevalence, Adoption, Illumina, Inc., Solution, Pharmaceutical industry, Illumina, Qiagen, Others, Workflow

SAN FRANCISCO, Jan. 4, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Next Generation Sequencing (NGS) Data Analysis - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Jan. 4, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Next Generation Sequencing (NGS) Data Analysis - Global Market Trajectory & Analytics" .
  • NGS data analysis encompasses primary, secondary and tertiary analysis steps, with some of these stages holding potential for automation through new sequencing solutions.
  • This segment currently accounts for a 44% share of the global Next Generation Sequencing (NGS) Data Analysis market.
  • Companies lacking the necessary infrastructure for data analysis, interpretation, and management are increasingly adopting cost-effective NGS data analysis services.

IHI Corporation Chooses AdaCore’s QGen Model-based Engineering Toolsuite to Develop Autonomous Factory Truck System Software

Retrieved on: 
Monday, December 13, 2021
Technology, Trucking, Engineering, Transport, Other Technology, Automotive Manufacturing, Manufacturing, Software, Networks, Ada, Qiagen, Defense, Code generation, IHI, Cyber Threat Intelligence Integration Center, Institute for Space and Defense Electronics, Urbanization, IHI Corporation, GNAT, Aircraft, Â, Safety, Travel, Energy & Environment, Transport, MISRA-C, Kawasaki Heavy Industries, Engineering, Efficiency, Multimedia, MATLAB, Association of Car Rental Industry Systems Standards, Microsoft Windows, Technology, 3D printing, Medical device, Risk management, Linux, Environment, Machine, Simulink

AdaCore today announced that IHI Corporation of Japan has chosen AdaCores QGen Model Verifier, a part of its QGen model-based engineering toolsuite, along with AdaCores expert support, to help them develop a safe and reliable autonomous truck system in a cost-effective manner.

Key Points: 
  • AdaCore today announced that IHI Corporation of Japan has chosen AdaCores QGen Model Verifier, a part of its QGen model-based engineering toolsuite, along with AdaCores expert support, to help them develop a safe and reliable autonomous truck system in a cost-effective manner.
  • IHI ultimately decided to adopt this approach and to use AdaCores QGen Model Verifier for Simulink to help validate their safety-critical system.
  • According to the IHI Technology & Intelligence Integration Center, We are developing an autonomous transport system using Simulink models.
  • AdaCore is thrilled that IHI has selected our QGen toolsuite to help develop its safety-critical autonomous truck system, said JC Bernedo, AdaCore QGen team lead.

Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

Retrieved on: 
Thursday, November 11, 2021
Qiagen, Chan, Drug development, Cancer, Therapy, Ingenuity, Toxic epidermal necrolysis, NASDAQ, Immunology, Entelo, CA, Tumor microenvironment, Novel, Amgen, Doctor of Philosophy, Stanford University, CDO, NYSE, QGEN, UCLA, Pharmaceutical industry

BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ --Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer.

Key Points: 
  • BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ --Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer.
  • Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer.
  • "Chan has significant experience advancing novel cancer therapies into clinical development," said Christopher Thanos, Ph.D., Chief Executive Officer of Actym Therapeutics.
  • Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer.

NEW GT-Digital SARS-CoV-2 Variant Assay Panel for QIAcuity® Wastewater Surveillance Kit (Patent Pending)

Retrieved on: 
Tuesday, November 9, 2021
Population, Qiagen, Cancer, Real-time, Polymerase, Patent pending, PCR, NWSS, Technology, Degenerative disease, CDC, Severe acute respiratory syndrome coronavirus 2, Multimedia, Policy, SARS, WBE, VOC, Lambda, QIAGEN, GTM, Television, Vaccine

The VOC kit targets 9 spike mutations and N1 which can be used to indicate the presence of 7 variants.

Key Points: 
  • The VOC kit targets 9 spike mutations and N1 which can be used to indicate the presence of 7 variants.
  • The workflow leverages QIAGEN's sample-preparation expertise and its innovative QIAcuity digital PCR system, which hosts GT Molecular's digital SARS-CoV-2 Wastewater Surveillance Assay.
  • The assay was developed to comply with the CDC guidelines for the United States National Wastewater Surveillance System (NWSS).
  • GT-Digital SARS-CoV-2 Wastewater Surveillance Assay for QIAcuity-Includes all necessary primers, probes and controls for detecting and normalizing SARS CoV-2 in wastewater.

Genialis Debuts ResponderID for Clinical Biomarker Discovery

Retrieved on: 
Tuesday, November 2, 2021
Medical Devices, Health, Technology, Software, Pharmaceutical, Biotechnology, Research, Cdx, Technology, Disease, Industry, Biodata, Drug development, PubMed, Database, CET, Patient, FDA, RUO, Central European, Doctor of Philosophy, Medicine, CEO, Biomarker, Environment, Multimedia, Qiagen, Solution, Therapy, Data analysis, Business development, Medical device, Pharmaceutical industry

As detailed in a whitepaper released today by Genialis, biomarkers measurably improve patient response rates and have been shown to enable clinical trials to achieve endpoints more quickly. In a retrospective modeling study of five major cancer indications, Parker and colleagues (2021) found clinical trials that used a biomarker for patient stratification -- in other words, predict which patients are more likely to respond to therapy -- were 5 to 12 times more likely to progress to the next phase. ResponderID has grown out of solutions to real-world challenges as discovered through work with innovative biotechs like InhibRx and OncXerna Therapeutics. OncXerna recently announced its lead biomarker, the XernaTM TME Panel, has been licensed by Qiagen for development as a companion diagnostic (CDx) and RUO kit.

Key Points: 
  • Genialis , a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced the launch of ResponderID, a new AI/ML-enabled platform specifically for use in clinical biomarker discovery.
  • Genialis built ResponderID to improve drug development timelines and help deliver more effective therapies to the right patient populations.
  • With ResponderID, Genialis helps its partners navigate these obstacles and solve myriad technical challenges to develop biomarker signatures for clinical discovery and eventual patient reporting.
  • ResponderID(), Genialis clinical biomarker discovery platform, defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development.

Global miRNA Sequencing and Assay Market Report 2021: Size, Trend & Forecast with Impact of COVID-19 to 2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 1, 2021
Health, Genetics, Safety, Growth, MicroRNA, Research, Vaccine, Industry, Ion semiconductor sequencing, Illumina, Inc., Degenerative disease, Library, Contract, Mirna, RNA, Nanopore sequencing, Academic institution, Ageing, COVID-19, Qiagen, Therapy, Population, Prevalence, Forest Law Enforcement and Governance Program, DNA, Animal, Medicinal plants

The "Global miRNA Sequencing and Assay Market: Size, Trend & Forecast with Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global miRNA Sequencing and Assay Market: Size, Trend & Forecast with Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.
  • The report provides an in-depth analysis of the global miRNA sequencing and assay market by value, by product, by end-users, by technology, by region.
  • The report also provides a detailed analysis of the COVID-19 impact on the miRNA sequencing and assay market.
  • miRNA sequencing is a parallel, next-generation sequencing technology for microRNAs that uses high-throughput DNA sequencing.